TICKERNERD
Menu
PDSBPDSBHealthcare · Biotechnology

PDSB Stock Forecast: PDS Biotechnology Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.29
−6.38% on the day

The 3 Wall Street analysts covering PDS Biotechnology Corp. hold a median 12-month price target of $4.75 — +1510.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$16.5M
Ticker Nerd rank
70 / 100
Median analyst target
$4.75
Analysts covering
3
Revenue$0.0
Operating income−$6.5M
Net income−$9.8M
Free cash flow−$2.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+34.0%
1M
+14.7%
YTD
−61.7%
1Y
−75.0%
From 52W high
−79.4%
From 52W low
+46.7%
$0.20
$1.43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PDSB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PDS Biotechnology Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Size
90
Issuance
73
Growth
68
Revisions
65
Value
46
Quality
30
Momentum
27
Volatility
18

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (18): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PDSB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PDSB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26PDSBHigh $5.00Median $4.75Low $4.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $4.50Median $4.75High $5.00

The green dot is the last close — the median target sits +1510.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Sept 2026HC Wainwright & Co.MaintainsBuy$7.00 → $5.00
26 Aug 2026HC Wainwright & Co.ReiteratesBuy$7.00
26 Aug 2026HC Wainwright & Co.ReiteratesBuy—
13 Aug 2026HC Wainwright & Co.MaintainsBuy$15 → $7.00
13 Aug 2026HC Wainwright & Co.MaintainsBuy—
15 Apr 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026HC Wainwright & Co.ReiteratesBuy$15
25 Nov 2025B. Riley SecuritiesMaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
1 July 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.MaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024B. Riley SecuritiesMaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
2 Oct 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDSB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PDSB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, PDS Biotechnology Corp. returned −75.0% against +17.5% for the S&P 500, dividends included.

PDSB vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26PDSBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PDSB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

PDS Biotechnology Corp. (PDSB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
−4.6×

Cheaper than 96% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−544.0%

Higher than 3% of US stocks

Return on assets
−70.6%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PDS Biotechnology Corp. (PDSB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PDS Biotechnology Corp. has a market value of $16.5M and an enterprise value of $15.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$33.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.8M.

  • Shares outstanding: 55.9M.

  • Trailing P/E: −0.4×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • PDS Biotechnology Corp. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PDSB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PDSBPDS Biotechnology Corp.$16.5M
70
ENLVEnlivex Ltd.$16.2M
40
PASGPassage Bio, Inc.$16.1M
43
BCDABioCardia, Inc.$16.1M
42
AEONAEON Biopharma, Inc.$16.3M
51
BIVIBioVie, Inc.$16.3M
26
CTXRCitius Pharmaceuticals, Inc.$15.9M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PDS Biotechnology Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PDSB news & analysis

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

GlobeNewsWire · 8 Sept 2026positive

PDS Biotechnology announced it has raised up to $22.55 million in equity funding through a private investment in public equity (PIPE) transaction, led by Dr. Patrick Soon-Shiong, founder of NantWorks. Dr. Soon-Shiong will join PDS Biotech's board of directors, and the company plans to progress development of its PDS0301 immunocytokine for solid tumors.

Why it matters — A PDSB watcher would care because the financing provides capital to advance its PDS0301 immunocytokine program and brings a prominent investor onto the board, which could support the company's clinical development efforts.

PDS Biotech Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026neutral

PDS Biotechnology Corporation reported its financial results for the quarter ended June 30, 2026, and provided a business and clinical programs update. The announcement was made in Princeton, N.J., on Aug. 13, 2026.

Why it matters — PDS Biotech watchers would care because the quarterly financial report and clinical programs update offer a current view of the company's cash position, expenditures, and pipeline progress.

FAQ

Frequently asked questions about PDSB stock

What is the PDSB stock price forecast for 2026-2027?

The 3 Wall Street analysts covering PDS Biotechnology Corp. have a median 12-month price target of $4.75, with estimates ranging from $4.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PDSB stock a buy right now?

Of the 3 analysts covering PDS Biotechnology Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PDS Biotechnology Corp. 70 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PDSB?

As at 12 Sept 2026, PDS Biotechnology Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will PDSB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1510.7% from the last close, and Ticker Nerd's factor model ranks PDS Biotechnology Corp. 70 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PDSB stock forecast for 2030?

No analyst covering PDS Biotechnology Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDSB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $5 over the next 12 months.

How has PDSB stock performed over the past year?

PDS Biotechnology Corp. returned -75.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PDS Biotechnology Corp. do?

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications.

What is the latest news on PDSB?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks". PDS Biotechnology announced it has raised up to $22.55 million in equity funding through a private investment in public equity (PIPE) transaction, led by Dr. Patrick Soon-Shiong, founder of NantWorks. Dr. Soon-Shiong will join PDS Biotech's board of directors, and the company plans to progress development of its PDS0301 immunocytokine for solid tumors.

Company

About PDS Biotechnology Corp.

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications. The company also works on tumor-targeted approaches that combine immune activation with precision delivery, supporting research across head and neck, cervical, prostate, anal, breast, and other cancers. PDS Biotechnology Corporation operates as a specialist in immuno-oncology, aiming to address areas where conventional treatments may be limited. Based in Princeton, New Jersey, the company focuses on advancing current product candidates through clinical development and commercialization efforts in the biopharmaceutical market.

CEO Dr. Frank K. Bedu-Addo Ph.D. · 21 employees · United States · https://www.pdsbiotech.com